sNN0029

DRUG3 trials

Sponsors

Newron Sweden AB

Conditions

Amyotrophic Lateral Sclerosis

Phase 1

A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis

CompletedNCT00800501

Newron Sweden ABAmyotrophic Lateral Sclerosis

Start: 2008-12-31End: 2011-06-30Updated: 2011-12-06

An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis

TerminatedNCT01384162

Newron Sweden ABAmyotrophic Lateral Sclerosis

Start: 2009-06-30End: 2015-10-31Updated: 2016-01-27

A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS

TerminatedNCT01999803

Newron Sweden ABAmyotrophic Lateral Sclerosis

Start: 2014-09-30End: 2015-10-31Updated: 2016-01-27